Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its earnings results on Monday, July, 31st. The company reported ($3.46) EPS for the quarter, beating the Zacks' consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to analysts' expectations of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company's quarterly revenue was up 459.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.14) EPS. View Intercept Pharmaceuticals' Earnings History.

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Intercept Pharmaceuticals.

15 brokerages have issued 12-month price objectives for Intercept Pharmaceuticals' stock. Their forecasts range from $69.00 to $350.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $213.31 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

• 1. Cantor Fitzgerald analysts commented, "In AESOP, OCA-treated PSC patients demonstrated significant decrease from baseline in alkaline phosphatase (ALP) of -22% compared with placebo-treated patients' increase of +1% at 24 weeks," the firm said."Additionally, CONTROL demonstrated atorvastatin's ability to reduce elevations of LDL-C in OCA-treated patients by 40-48mg/dL." (8/8/2017)
• 2. According to Zacks Investment Research, "Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. A potential label expansion of the drug will further boost sales. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry in the last one year." (7/11/2017)
• 3. Cowen and Company analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)
• 4. BMO Capital Markets analysts commented, "We are raising our PT to $221 from $198 as we believe updated launch metrics suggest continued steady uptake of Ocaliva for PBC driven by greater physician awareness and more open access, supporting our above-consensus 2017 sales estimates. We believe the removal of the REGENERATE enrollment overhang could allow ICPT shares to trade up meaningfully on any signs of efficacy in PSC Ph2 as it remains a source of upside to our and Street estimates. We expect Ocaliva sales growth and development milestones to help ICPT shares recover." (2/24/2017)
• 5. Wedbush analysts commented, "We believe several clinical catalysts later this year could provide upside to ICPT's current price. Q4/FY:16 Financials: Q4/FY:16 Ocaliva sales were $13.4MM/$18.2MM. Revenues of $13.8MM/$24.9MM also came in higher than consensus estimates of $8.96MM/$20.16MM. GAAP (loss) of $(4.84)/$16.74) came in lower than consensus estimates of $(3.68)/($15.63) on higher than expected SG&A expenses. We have incorporated Q4/FY:16 financials and updated our model based on 2017 guidance. ICPT ended 2016 with cash balance of $689.4MM. Progress on the Ocaliva launch. ICPT appears to be making significant progress with reimbursement, with the time to filled-prescription now at three weeks." (2/24/2017)

Some companies that are related to Intercept Pharmaceuticals include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), GW Pharmaceuticals PLC (GWPH), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), NovoCure Limited (NVCR) and Halozyme Therapeutics (HALO).

Intercept Pharmaceuticals' management team includes the folowing people:

• Paolo Fundaro, Independent Chairman of the Board
• Mark Pruzanski M.D., President, Chief Executive Officer, Director
• Sandip S. Kapadia, Chief Financial Officer, Treasurer
• Lisa Bright, President, International
• Jerome Benedict Durso, Chief Operating Officer
• David Ford, Chief Human Resource Officer
• Richard Kim, Senior Vice President, Commercial U.S.
• Rachel L. McMinn Ph.D., Chief Business and Strategy Officer
• David M. Shapiro M.D., Chief Medical Officer
• Srinivas Akkaraju M.D. Ph.D., Independent Director

Intercept Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Carmignac Gestion (8.11%), Capital World Investors (7.67%), Vanguard Group Inc. (5.31%), State Street Corp (2.99%) and First Trust Advisors LP (1.15%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Klaus R Dr Veitinger, Lisa Bright, Mark Pruzanski, Nicole Williams, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Marshall Wace North America L.P., Capital World Investors, State Street Corp, UBS Asset Management Americas Inc., Macquarie Group Ltd., AXA and Schwab Charles Investment Management Inc.. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.

Intercept Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Vanguard Group Inc., First Trust Advisors LP, Quantitative Investment Management LLC, Asymmetry Capital Management L.P., FMR LLC, Sphera Funds Management LTD. and Northern Trust Corp. View Insider Buying and Selling for Intercept Pharmaceuticals.

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $104.08.